64.03
0.31%
-0.20
After Hours:
64.13
0.10
+0.16%
Lemaitre Vascular Inc stock is currently priced at $64.03, with a 24-hour trading volume of 73,547.
It has seen a -0.31% decreased in the last 24 hours and a -3.63% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $63.81 pivot point. If it approaches the $64.84 resistance level, significant changes may occur.
Previous Close:
$64.23
Open:
$63.72
24h Volume:
73,547
Market Cap:
$1.44B
Revenue:
$193.48M
Net Income/Loss:
$30.11M
P/E Ratio:
52.92
EPS:
1.21
Net Cash Flow:
$29.49M
1W Performance:
+1.57%
1M Performance:
-3.63%
6M Performance:
+29.30%
1Y Performance:
+16.65%
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 Second Avenue, Burlington, MA
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-06-23 | Initiated | Oppenheimer | Outperform |
Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Sep-16-21 | Initiated | Jefferies | Buy |
Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Jul-25-19 | Reiterated | Barrington Research | Outperform |
Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
Jun-08-18 | Resumed | ROTH Capital | Buy |
Apr-26-18 | Downgrade | Stifel | Buy → Hold |
Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
Mar-21-17 | Initiated | First Analysis Sec | Overweight |
Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
Jul-28-16 | Reiterated | Barrington Research | Outperform |
Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
GlobeNewswire Inc.
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
Zacks Investment Research
Here's Why You Should Retain Medtronic (MDT) Stock for Now
Zacks Investment Research
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Zacks Investment Research
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Zacks Investment Research
Here's Why You Should Add DaVita (DVA) to Your Portfolio
Zacks Investment Research
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Lemaitre Vascular Inc (LMAT) Revenue 2024
LMAT reported a revenue (TTM) of $193.48 million for the quarter ending December 31, 2023, a +19.69% rise year-over-year.
Lemaitre Vascular Inc (LMAT) Net Income 2024
LMAT net income (TTM) was $30.11 million for the quarter ending December 31, 2023, a +45.89% increase year-over-year.
Lemaitre Vascular Inc (LMAT) Cash Flow 2024
LMAT recorded a free cash flow (TTM) of $29.49 million for the quarter ending December 31, 2023, a +33.13% increase year-over-year.
Lemaitre Vascular Inc (LMAT) Earnings per Share 2024
LMAT earnings per share (TTM) was $1.34 for the quarter ending December 31, 2023, a +44.09% growth year-over-year.
About Lemaitre Vascular Inc
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
Cap:
|
Volume (24h):